Silicogenix Partners with BioDuro to Accelerate AI-Driven Drug Discovery for Complex Diseases
核心洞察
Silicogenix (搜索), a pioneer in AI-powered small molecule (搜索) design technology, has formed a strategic partnership with global CRDMO BioDuro (搜索) to streamline drug discovery for complex and rare diseases (搜索).
The collaboration combines SGX's proprietary polypharmacology frameworks with BioDuro (搜索)'s integrated drug discovery platform to reduce development costs and timelines from concept to preclinical stages.
SGX's technology enables access to the majority of the human proteome (搜索) and supports novel therapeutic approaches including combination therapies with standard-of-care treatments.
Silicogenix (搜索) (SGX), a pioneer in fit-for-purpose small molecule (搜索) design technology, has announced a strategic partnership with BioDuro (搜索), a global Contract Research, Development, and Manufacturing Organization (CRDMO), to accelerate novel drug discovery for complex diseases (搜索). The collaboration aims to lower cost and time barriers in developing complex therapies by combining SGX's proprietary AI-driven frameworks with BioDuro's comprehensive drug discovery platform.
Revolutionary Technology Platform
SGX's technology platform enables biopharmaceutical companies to rapidly initiate and test new therapies through its ability to access the majority of the human proteome (搜索). The company's proprietary, ultra-fast, and high-throughput frameworks enable novel approaches to drug discovery that have been previously inaccessible to experimental methods. By leveraging both target and molecule diversity, the platform supports polypharmacology and non-traditional drug development approaches.
"SGX's technology enables biopharma companies to rapidly initiate and test new therapies, including possible combinations with standard-of-care treatments, due to their ability to access the majority of the human proteome (搜索)," according to the partnership announcement.
Strategic Collaboration Benefits
The partnership leverages BioDuro (搜索)'s leading drug discovery platform to deliver various complex molecules at speed, enabling the novel platform to accelerate drug discovery through to preclinical development at reduced costs. BioDuro brings 29 years of proven track record as a CRDMO, with global presence spanning 7 sites across the United States and China and over 2,000 employees.
"We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery," said Dr. Subas Sakya, Chief Scientific Officer at BioDuro (搜索). "We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics that will save lives."
Focus on Complex Disease Areas
The collaboration specifically targets complex and rare diseases (搜索), with SGX's technology platform designed for developing modern, first-in-class oncology and immunology therapeutics. The company's approach is backed by nearly 100 years of combined experience in pharmaceutical development and artificial intelligence.
"This is a pivotal moment for the pharmaceutical industry, and this partnership is a significant step forward for how novel treatments for complex and rare diseases (搜索) can be quickly brought to market," said Dr. Shailesh Date, Co-founder of Silicogenix (搜索). "BioDuro (搜索) is an undisputed leader and we believe our collective approach will help pharmaceutical companies greatly expedite the development cycle for therapeutics that address unmet medical needs."
Integrated Service Platform
BioDuro (搜索) specializes in both small and large molecule discovery, development, scale-up, and manufacturing, offering fully integrated services from early drug discovery to commercial manufacturing. Their capabilities span chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product development, providing a comprehensive platform for the partnership's objectives.
The collaboration represents a significant advancement in streamlining the path from concept to preclinical development for the biopharmaceutical industry, potentially transforming how novel treatments for complex diseases (搜索) are brought to market.